Köpenysejtes limfóma: vizsgálatok itt: Kína

In Kína 41 Also abroad 150

41 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Where
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou
Életkor
18 év and over
People
182 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06084936
1. fázisTaking people
Phase Ib Clinical Study of Keynatinib
Where
Beijing, Chengdu, Shanghai
Életkor
18 év and over
People
75
Run by
Medolution Ltd.
See details and how to joinNCT04807881
3. fázisTaking people
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Where
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
Életkor
18 év and over
People
300 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06742996 · EU 2024-515593-27-00
1/2. fázisTaking people
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Where
Beijing, Guangzhou, Jinan, Tianjin, Zhengzhou
Életkor
18 év and over
People
408 worldwide
Run by
AstraZeneca
See details and how to joinNCT06564038 · EU 2024-515034-33-00
1/2. fázisTaking people
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Where
Beijing, Guangzhou, Suzhou
Életkor
18 év and over
People
258 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06697184 · EU 2024-518829-15-00
1/2. fázisTaking people
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Where
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Qingdao, Shanghai, Suzhou, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiangyang, Zhengzhou
Életkor
18 év and over
People
146
Run by
BeOne Medicines
See details and how to joinNCT05294731
1. fázisTaking people
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Where
Zhengzhou
Életkor
18 év and over
People
180 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT07424833
1/2. fázisTaking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Beijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
Életkor
18 év and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
2. fázisNot yet taking people in Kína
A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
Where
Guangzhou, Shanghai
Életkor
18 év and over
People
188
Run by
TransThera Sciences (Nanjing), Inc.
See details and how to joinNCT07855016
1/2. fázisTaking people
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Where
Hangzhou, Shanghai
Életkor
18 év and over
People
174 worldwide
Run by
AstraZeneca
See details and how to joinNCT06542250
No phaseCsak meghívásos
Real-world Study of Acalabrutinib
Where
Shanghai
Életkor
18 év and over
People
160
Run by
Ruijin Hospital
See details and how to joinNCT06767891
1/2. fázisTaking people
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Where
Hangzhou
Életkor
18 év to 75 év
People
70
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07788118
3. fázisNot yet taking people in Kína
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
Where
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xian, Zhengzhou
Életkor
18 év and over
People
280
Run by
Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT07784101
1/2. fázisTaking people
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Where
Tianjin
Életkor
18 év and over
People
92
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07609862
2. fázisTaking people
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
Where
Shanghai
Életkor
14 év and over
People
25
Run by
Ruijin Hospital
See details and how to joinNCT07272499
2. fázisTaking people
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Where
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Hengyang, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Wuhan, Xian, Xinjiang, Yibin, Zhengzhou
Életkor
18 év and over
People
75
Run by
Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT07082686
2. fázisTaking people
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
Where
Changzhou, Nanjing
Életkor
18 év and over
People
39
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07719556
2. fázisNot yet taking people in Kína
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
Where
Zhengzhou
Életkor
18 év and over
People
45
Run by
Henan Cancer Hospital
See details and how to joinNCT07684950
No phaseNot yet taking people in Kína
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
Where
Suzhou
Életkor
18 év and over
People
30
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07609446
2. fázisTaking people
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Where
Tianjin
Életkor
18 év to 80 év
People
37
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07261163
2. fázisTaking people
CD70-targeted immunoPET Imaging of Malignant Cancers
Where
Shanghai
Életkor
18 év to 80 év
People
300
Run by
RenJi Hospital
See details and how to joinNCT06852638
1. fázisNot yet taking people in Kína
The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL
Where
Shanghai
Életkor
18 év and over
People
28
Run by
Ruijin Hospital
See details and how to joinNCT07548255
No phaseNot yet taking people in Kína
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
Where
Langfang
Életkor
18 év to 75 év
People
69
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07476378
2. fázisTaking people
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Where
Beijing
Életkor
18 év to 80 év
People
43
Run by
Peking University Third Hospital
See details and how to joinNCT07460362
3. fázisTaking people
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Where
Beijing, Nanning
Életkor
18 év and over
People
394
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07377578